A safety review, including meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention, has concluded that the recommended pause on the use of the Johnson & Johnson COVID-19 vaccine in the U.S. must be lifted and use of the vaccine should be resumed.

The pause on the vaccine’s use was recommended following six reports of a rare and severe type of blood clot after administration of the Janssen COVID-19 vaccine. Experts at the FDA and CDC assessed the available data to evaluate the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body, in association with thrombocytopenia. The agencies determined that use of the vaccine should be resumed in the United States. The agencies are confident that the vaccine is safe and effective in preventing COVID-19. The FDA also determined that according to available data, the known and potential benefits of the vaccine outweigh its known and potential risks in people aged 18 years and above… (CDC, April 23, 2021)